US2015299705A1PendingUtilityA1

Methods and compositions involving mirna and mirna inhibitor molecules

63
Assignee: ASURAGEN INCPriority: Nov 12, 2004Filed: Jun 12, 2015Published: Oct 22, 2015
Est. expiryNov 12, 2024(expired)· nominal 20-yr term from priority
Inventors:David BrownLance FordAngie ChengRich JarvisMike ByromDmitriy OvcharenkoEric DevroeKevin Kelnar
A61P 37/00A61P 43/00A61P 9/10A61P 35/00A61P 25/00A61P 31/00A61P 31/06A61P 25/28A61P 35/02A61P 17/02A61P 17/00A61P 11/00A61P 15/08C12N 2310/3527C12N 15/111A61K 31/713C12N 2310/322C12N 15/1136C12Q 2600/158A61K 45/06A61K 31/7105C12N 2320/30A61N 5/10C12N 2310/14A61K 31/7088C12N 2310/351C12N 2310/321A61K 9/127C12N 15/113C12N 2330/10C12N 2310/35C12Q 1/68C12N 2310/533C12N 2310/33C12N 2310/141C12N 2310/344C12N 2310/312C12N 2320/12C12N 2310/3535C12N 2320/50C12Q 1/6876C12Q 2600/178
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating glioblastoma in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of a miRNA inhibitor comprising a nucleic acid sequence that is at least 90% complementary to a miR-10b sequence. 
     
     
         2 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to 5-110 nucleotides of SEQ ID NO: 21. 
     
     
         3 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 50 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         4 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 25 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         5 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 22 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         6 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 20 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         7 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 15 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         8 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 10 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         9 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to at least 5 contiguous nucleotides of SEQ ID NO: 79. 
     
     
         10 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to nucleotides 27-48 of SEQ ID NO: 21. 
     
     
         11 . The method of  claim 1 , wherein the miRNA inhibitor comprises a sequence that is at least 90% complementary to a mature, naturally-occurring miR-10b sequence. 
     
     
         12 . The method of  claim 1 , wherein the miRNA inhibitor further comprises a pendant group conjugated to an end of the nucleic acid sequence. 
     
     
         13 . The method of  claim 1 , wherein the miRNA inhibitor is administered subcutaneously or intravenously.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.